Patent · US Active

Anti-PD-L1 antibodies and diagnostic uses thereof

US10689445B2 · kind B2 · utility

1Cited by

3References

28Claims

0Family size

Assignees

Ventana Medical Systems, Inc. · US
Spring BioScience Corporation · US

Inventors

Marcin KOWANETZ · San Francisco, US
Hartmut Koeppen · San Mateo, US
Zachary BOYD · Oakland, US
Zhiming Liao · Livermore, US
Yifei Zhu · Alpharetta, US
Bharathi Vennapusa · Tucson, US
Patrick Roche · Tullow, IE

Key dates

Filing date	Oct 6, 2017
Grant date	Jun 23, 2020
Priority date	—
Expiry date	Jul 21, 2038

Classification

Technology area (CPC G)Physics
CPC primaryG01N2500/10
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.